ADC Therapeutics SA — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
▼ Likely negative
significance 52/100
What the filing says
ADC Therapeutics granted retention incentive awards to three key executives on June 30, 2026: Ameet Mallik (Chairman) received $1,795,500 cash + 675,000 RSUs; Pepe Carmona received $541,842 cash + 203,700 RSUs; Mohamed Zaki received $568,974 cash + 213,900 RSUs. Total cash outlay: $2,906,316; total RSU grant: 1,092,600 units. All awards vest by June 30, 2027 or upon termination without cause/for good reason, conditioned on continued employment.
Why this rating
Cash payout ($2.9M) = 2.1% of $136.4M market cap—meaningful but not transformational. RSU dilution material but vesting contingent. Suggests retention urgency; possible distress signal or M&A positioning. Ordinary executive incentive practice, yet concentrated outlay warrants scrutiny for cash runway.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.